{
    "2019-08-26": [
        [
            {
                "time": "2019-08-27",
                "original_text": "恒瑞医药：公司及子公司药品获药监局临床试验通知书",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "药品",
                        "临床试验",
                        "通知书"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-26",
                "original_text": "8月26日复盘:假阳线里要看到真东西 主力重点出击1股",
                "features": {
                    "keywords": [
                        "复盘",
                        "假阳线",
                        "主力",
                        "出击"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-08-27",
                "original_text": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗(SHR-1210)获批临床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "卡瑞利珠单抗",
                        "临床试验",
                        "获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-27",
                "original_text": "龙津药业封涨停多只个股大涨 医药产业链板块有“抗跌”疗效？",
                "features": {
                    "keywords": [
                        "龙津药业",
                        "涨停",
                        "医药产业链",
                        "抗跌"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-26",
                "original_text": "申万宏源一周晨会纪要合集（2019/8/26-2019/8/30）",
                "features": {
                    "keywords": [
                        "申万宏源",
                        "晨会纪要",
                        "合集"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-08-26",
                "original_text": "【川财研究所*四季度展望】医药生物：板块迎来估值切换，关注四季度业绩优异个股",
                "features": {
                    "keywords": [
                        "川财研究所",
                        "医药生物",
                        "估值切换",
                        "四季度",
                        "业绩"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-27",
                "original_text": "大额“花式”减持频现 今年以来上市公司高管减持逾5500次 减持股份数量",
                "features": {
                    "keywords": [
                        "减持",
                        "上市公司",
                        "高管",
                        "5500次"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-08-27",
                "original_text": "白马股何以批量创新高",
                "features": {
                    "keywords": [
                        "白马股",
                        "创新高"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}